Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations

[1] Borghaei H(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639

[2] Paz-Ares L(2015)Recurrent antibiotic exposure may promote cancer formation—another step in understanding the role of the human microbiota? Eur J Cancer 51 2655-2664

[3] Horn L(2020)Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma Medicine (baltimore) 99 209-215

[4] Boursi B(2019)Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis Oncotarget 10 36-54

[5] Mamtani R(2015)Targeted therapy for non-small cell lung cancer: current standards and the promise of the future Transl Lung Cancer Res 4 671228-ii32

[6] Haynes K(2021)Pembrolizumab plus chemotherapy or anlotinib vs. pembrolizumab alone in patients with previously treated EGFR-Mutant NSCLC Front Oncol 11 ii31-1444

[7] Bylicki O(2019)Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations Ann Oncol 30 7700023-1846

[8] Guisier F(2021)Immune checkpoint inhibitors plus single-agent chemotherapy for advanced non-small-cell lung cancer after resistance to EGFR-TKI Front Oncol 11 1437-4593

[9] Monnet I(2018)Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer Ann Oncol 29 1837-1155

[10] Cavanna L(2017)EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer Oncoimmunology 6 4585-1372

[1] Borghaei H(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639

[2] Paz-Ares L(2015)Recurrent antibiotic exposure may promote cancer formation—another step in understanding the role of the human microbiota? Eur J Cancer 51 2655-2664

[3] Horn L(2020)Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma Medicine (baltimore) 99 209-215

[4] Boursi B(2019)Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis Oncotarget 10 36-54

[5] Mamtani R(2015)Targeted therapy for non-small cell lung cancer: current standards and the promise of the future Transl Lung Cancer Res 4 671228-ii32

[6] Haynes K(2021)Pembrolizumab plus chemotherapy or anlotinib vs. pembrolizumab alone in patients with previously treated EGFR-Mutant NSCLC Front Oncol 11 ii31-1444

[7] Bylicki O(2019)Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations Ann Oncol 30 7700023-1846

[8] Guisier F(2021)Immune checkpoint inhibitors plus single-agent chemotherapy for advanced non-small-cell lung cancer after resistance to EGFR-TKI Front Oncol 11 1437-4593

[9] Monnet I(2018)Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer Ann Oncol 29 1837-1155

[10] Cavanna L(2017)EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer Oncoimmunology 6 4585-1372